SCM
RXRX icon

Sterling Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Sterling Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.14K Buy
2,976
+540
+22% +$2.09K ﹤0.01% 2415
2025
Q4 		$9.96K Buy
2,436
+1,547
+174% +$7.66K ﹤0.01% 2602
2025
Q3 		$4.34K Buy
889
+68
+8% +$357 ﹤0.01% 2800
2025
Q2 		$4.15K Buy
821
+556
+210% +$2.73K ﹤0.01% 2611
2025
Q1 		$1.4K Buy
265
+15
+6% +$109 ﹤0.01% 2703
2024
Q4 		$1.69K Buy
250
+12
+5% +$81 ﹤0.01% 2824
2024
Q3 		$1.57K Buy
+238
New +$1.71K ﹤0.01% 2310

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sterling Capital Management's RXRX Position: Q1 2026 in Review

Sterling Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 22% in Q1 2026, buying an estimated $2.09K and bringing the position to 2,976 shares worth $9.14K. The position accounts for ﹤0.01% of the portfolio, ranked #2415.

Sterling Capital Management first reported a position in RXRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $9.96K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Sterling Capital Management held 2,976 shares of Recursion Pharmaceuticals worth $9.14K as of Q1 2026.
  • Sterling Capital Management bought 540 Recursion Pharmaceuticals shares in Q1 2026, an estimated $2.09K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2415 holding.
  • Sterling Capital Management first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Recursion Pharmaceuticals position peaked at $9.96K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.